• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Yijia,LUO Liping,LIU Yanzhi.Clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis[J].Journal Of Pharmaceutical Research,2017,36(10):596-601[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3712times   Download 3467次 QR Code for this article
Scan with your phone!
Denosumab治疗绝经后骨质疏松症的临床研究进展
张益嘉1,罗丽平1,刘衍志2
Font:Larger+|Default|Smaller-
(1.珠海市丽珠单抗生物技术有限公司,广东 珠海 519045;2.广东天然药物研究与开发重点实验室,广东医科大学,广东 湛江 524023)
摘要:
狄诺塞单抗(Denosumab)是首个上市的抗RANKL治疗性单克隆抗体产品,主要用于治疗骨质疏松症和其他骨骼疾病。本文主要综述其近年国外治疗绝经后骨质疏松症的临床研究进展。
关键词:  Denosumab  核因子κB受体活化因子配体  绝经后骨质疏松症  临床研究
DOI:10.13506/j.cnki.jpr.2017.10.011
基金项目:
Clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis
ZHANG Yijia,LUO Liping1,LIU Yanzhi2
(1.Livzon Mabpharm Inc.,Zhuhai 519045,China;2.Guangdong Key Laboratory for R&D of Natural Drugs,Guangdong Medical University,Zhanjiang 524023,China)
Abstract:
Denosumab is the first marketed product of anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) monoclonal antibody for the treatment of osteoporosis and other bone diseases.The clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis was reviewed in this article.
Key words:  Denosumab  RANKL  Postmenopausal osteoporosis  Clinical study
Today's Visits:464    Total Visits:2383159
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.